This page provides a timely snapshot of our most recent negotiation activity, including an overview of open files and updates on key milestones from the past 4 weeks.
How current is this information?
The content on this page is updated on an ongoing basis to reflect the most recent available information. Please note that updates about negotiation activity may take 1–2 weeks to be processed.
“Under consideration for negotiation” means we’re currently considering the evidence and gathering other information to inform the negotiation approach, including the drug’s eligibility for expedited negotiation pathways. Once negotiation activities are underway, the drug is in active negotiation.
Letters of engagement
We send letters of engagement (LOE) to manufacturers at the end of the consideration phase, to begin active negotiations. The drugs listed below have recently entered active negotiation.
| Brand name | Manufacturer | Indication | LOE date |
|---|---|---|---|
| Ayvakyt | Medison Pharma Canada Inc. | For the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment. | 2026-10-07 |
| Elahere | AbbVie Corporation | For the treatment of adults with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens |
2026-09-23 |
| Lunsumio IV | Hoffmann-La Roche Ltd. | As monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (Grades 1 – 3a) who have received at least two prior lines of systemic therapy. | 2026-09-18 |
| Lunsumio SC | Hoffmann-La Roche Ltd. | As monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (Grades 1 – 3a) who have received at least two prior lines of systemic therapy. | 2026-09-18 |
| Lupron Depot | AbbVie Corporation | Advanced prostate cancer | 2026-09-25 |
Letters of intent
A letter of intent (LOI) outlines the negotiated terms of an agreement between the pCPA and a manufacturer at the end of a successful negotiation. The list below reflects our latest LOIs.
| Title | Manufacturer | Indication | LOE date | LOI date |
|---|---|---|---|---|
| Gonal-F | EMD Serono Canada, a division of EMD Inc. | Luveris, for the stimulation of follicular development in women, as part of an assisted procreation activity, administered concomitantly with follitropin | 2026-07-07 | 2026-10-13 |
| Luveris | EMD Serono Canada, a division of EMD Inc. | For the stimulation of follicular development in women, as part of an assisted procreation activity, administered concomitantly with follitropin | 2026-07-07 | 2026-10-13 |
| Blenrep (belantamab mafodotin) | GlaxoSmithKline Inc. | For the treatment of multiple myeloma in combination with pomalidomide and dexamethasone (Bpd) in adult patients who have received at least one prior therapy including lenalidomide. | 2026-04-30 | 2026-09-18 |
| Blenrep (belantamab mafodotin) | GlaxoSmithKline Inc. | For the treatment of multiple myeloma in combination with bortezomib and dexamethasone (BVd) in adult patients who have received at least one prior therapy. | 2026-04-30 | 2026-09-18 |
| Iqirvo | Ipsen Biopharmaceuticals Canada, Inc. | Primary biliary cholangitis | 2025-08-21 | 2026-09-21 |
| Tevimbra | In combination with gemcitabine and platinum chemotherapy, for the first-line treatment of adult patients with recurrent or metastatic nasopharyngeal carcinoma (NPC). | 2026-07-02 | 2026-09-25 | |
| Loqtorzi | Apotex Inc. | In combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC). | 2026-07-02 | 2026-10-13 |
Negotiations ended without agreement
Both negotiating parties strive to reach timely agreements. In rare cases, alignment between manufacturers and the pCPA can’t be reached. Each negotiation is unique, and decisions are made based on the information available at the time.
The pCPA always welcomes unsolicited offers, should a manufacturer want to re-engage and go back to the negotiation table.
When agreements can’t be reached, public drug plans may make decisions about providing coverage through their exceptional access programs.
There have been no negotiations completed without agreement in the last four weeks
Negotiations that weren’t pursued - Last 4 weeks
We don’t pursue negotiations in cases where the drug’s health technology assessment (HTA) recommendations were negative or “do not reimburse.” Other reasons, such as the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected on the drug’s page in the database.
| Title | Manufacturer | Indication | Close date |
|---|---|---|---|
| Opzelura | Incyte Biosciences Canada Corporation | Nonsegmental vitiligo | 2026-09-17 |
| Imaavy | Janssen Inc. | An add-on to standard therapy for the treatment of Generalized myasthenia gravis (gMG) in adult and adolescent patients aged 12 years and older who are anti-AChR or anti-MuSK antibody positive. | 2026-09-18 |
| Minjuvi | Incyte Biosciences Canada Corporation | In combination with lenalidomide for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, who are not eligible for autologous stem cell transplant (ASCT). | 2026-09-21 |